The Canadian Task Force on Preventative Health Care (CTFPHC) released a report on Monday that recommends not using the prostate specific antigen (PSA) test for prostate cancer screening.

The CTFPHC’s recommendations come after an extensive evidence review process that show the potential harms of screening outweigh the potential benefits for most people. Potential harms include false-positivies and over diagnosis, which could result in unnecessary treatments including surgery and radiation. These treatments have the potential to cause sexual, urinary, and bowel complications for men.

Dr. Murray Krahn, a lead clinical methodologist for the MaRS EXCITE program, and Director of the Toronto Health Economics and Technology Assessment Collaborative (THETA) was interviewed by CBC’s Matt Galloway on Metro Morning to comment on the CTFPHC’s report. Dr. Krahn believes that a thoughtful discussion should take place between the primary care doctor and the patient on the benefits and risks of the test saying, “the clinical evidence is really complicated and you have to also consider how men feel about the outcomes treatment, for some men preservation of sexual function, preservation of urinary function is really important and for other men that may be less important set in the context of reducing prostate cancer mortality.”

Listen to the full interview here.

THETA is currently overseeing the EXCITE evaluation of iDaptSomno’s ApneaDx device and RNA Diagnostics’ RNA disruption assay.

Lily Lo

Lily manages the Procurement by Co-Design challenges to ensure effective collaboration between healthcare providers and vendors. See more…